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Background: Molecular heterogeneity of tumors suggests the presence of multiple different subclones that may
limit response to targeted therapies and contribute to acquisition of drug resistance, but its quantification has
remained challenging.
Results: We performed simulations to evaluate statistical measures that best capture the molecular diversity within
a group of tumors for either continuous (gene expression) or discrete (mutations, copy number alterations)
molecular data. Dispersion based metrics in the principal component space best captured the underlying
heterogeneity. To demonstrate utility of these measures, we characterized the diversity in transcriptional and
genomic profiles of different breast tumor subtypes, and showed that basal-like or triple-negative breast cancers
(TNBC) are significantly more heterogeneous molecularly than other subtypes. Our analysis also suggests that
transcriptional diversity is a global characteristic of the tumors observed across the majority of molecular pathways.
Among basal-like tumors, those that were resistant to multi-agent chemotherapy showed greater transcriptional
diversity compared to chemotherapy-sensitive tumors, suggesting that potentially multiple mechanisms may be
contributing to chemotherapy resistance.
Conclusions: We proposed and validated measures of transcriptional and genomic diversity that can quantify the
molecular diversity of tumors. We applied the new measures to genomic data from breast tumors and
demonstrated that basal-like breast cancers are significantly more diverse than other breast cancers. The observation
that chemo-resistant tumors are significantly more diverse molecularly than chemosensitive tumors implies that
multiple resistance mechanisms may be active, thus limiting the sensitivity and accuracy of predictive markers of
chemotherapy response.
Keywords: Tumor diversity, Breast cancer, Basal-like subtype, Chemotherapy resistance, Dispersion distance,
Hamming distance, ChemotherapyBackground
Pathologists have long recognized that tumors are highly
heterogeneous consisting of neoplastic cells with distinct
morphological and molecular features that are associated
with clinically distinct phenotypes [1]. In the past few years,
large-scale next-generation sequencing provided evidence
of extensive genomic diversity in histopathologically
similar cancers, with each tumor effectively harboring a
unique repertoire of genomic abnormalities [2-5]. Epi-
genetic changes that occur throughout tumorigenesis* Correspondence: christos.hatzis@yale.edu
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unless otherwise stated.and the environmental cues conveyed through a tumor’s
microenvironment contribute to the observed phenotypic
heterogeneity, but genetic alterations are thought to drive
the majority of tumor phenotypic variation [6].
The early large scale transcriptional profiling efforts
provided the initial impetus for characterizing the
phenotypic heterogeneity of cancer that allowed to
discover transcriptionally-uniform cancer subtypes that
were associated with distinct clinical outcomes [7,8].
These subtypes were subsequently shown by next gener-
ation sequencing to be molecularly and genomically
quite heterogeneous [9]. Although the causal drivers of
intertumor heterogeneity are not clearly understood
[10], genomic instability appears to be a unifying themetd. This is an Open Access article distributed under the terms of the Creative
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deregulate the control of DNA replication thus promot-
ing proliferation and destabilizing the genome [11]. The
increased clonal diversity that results from genetic
instability is associated with a higher risk of progression
[12], worst survival [13] and resistance to chemotherapy
[14]. A recent study reported that the pre-treatment
genomic diversity among cells from each of the four
breast cancer subtypes is preserved after chemotherapy,
but tumors with lower genetic diversity before treat-
ment are more likely to achieve complete pathologic
response (pCR), irrespective of phenotypic subtype [15].
Breast tumors of the basal-like or triple negative breast
cancer (TNBC) subtype exhibit a broad range of com-
plex structural DNA alterations [4,16] that render them
particularly challenging to treat effectively as a group
with standard cytotoxic chemotherapy or with targeted
therapies. Because a tumor’s transcriptional profile is an
amalgam of the functional genetic and epigenetic varia-
tions that it harbors, higher intratumor genetic hetero-
geneity would be reflected in greater transcriptional
diversity or dissimilarity between tumors of the same
phenotype. Such transcriptional diversity could be the
reason why developing gene-expression based predictors
of chemotherapy sensitivity for basal-like cancer has
been unexpectedly difficult [17,18]. The term diversity is
used here to denote the dissimilarity in gene expression
or mutational profiles between individuals, which is a
characteristic of a group of tumors, while the term
heterogeneity here refers to the non-uniformity in gen-
etic and cellular composition of an individual tumor.
In this paper we evaluated through extensive simula-
tions a number of statistical metrics based on the pairwise
similarity of transcriptional and genomic profiles and
selected mean dispersion distance as the best measure of
transcriptional diversity. Using this measure, we observed
that among basal-like breast cancers, those that were
chemotherapy resistant were significantly more diverse
than chemotherapy sensitive cancers. These results sug-
gest that multiple resistance mechanisms may be active
among cancers of the same subtype and such heterogen-
eity would need to be accounted for when developing
predictive models of response to chemotherapy.
Results
Evaluation of transcriptional diversity metrics in
simulated datasets
We used two different strategies to assess transcriptional
diversity among a group of profiles. In the first strategy,
we considered all possible pairwise distances among the
profiles the group using Pearson or cosine correlation
for pairwise similarity of transcriptional profiles. In the
second strategy, we used a dispersion distance metric to
summarize the diversity as distance from the populationcentroid [19] (details in Methods). We considered either
the mean or the median of the distribution of pairwise or
dispersion distances as a summary of the central tendency
in the group. To evaluate the performance of the different
metrics, we generated artificial gene expression datasets
representing scenarios that differed in the number of
latent subgroups present and in the within (σg) and
between (σp) tumor sample variance using the R package
Umpire [20]. In each scenario, the log expression level for
each gene was generated by a hierarchical model, in which
σg controls the within-tumor variance and σp controls the
variance across patients in the cohort [21].
Figure 1A shows eight simulated scenarios (50 genes per
sample, 40 samples per cohort) corresponding to 1, 2, 4,
and 40 even-sized latent intra-cohort subgroups, and
two levels of relative between and within-tumor variation
(σp /σg = 0.5/1.5 and 0.5/0.5). A smaller σp/σg ratio indi-
cates lower relative variation across tumors and therefore
higher similarity in their expression profiles or lower over-
all diversity, whereas a larger σp/σg ratio or a greater num-
ber of latent subgroups implies greater within cohort
diversity. The mean of all within-group pairwise distances
was calculated for each scenario repeatedly over 500 inde-
pendent simulations from the same distributions. All met-
rics consistently increased with increasing number of
latent subgroups and σp/σg ratio, except for the cosine
metric that exhibited lower sensitivity when the relative
between and within-tumor variation was high (Figure 1B).
The mean dispersion distance tracked almost linearly
the increase in heterogeneity due to increasing propor-
tion in a two latent subgroup scenario (Figure 1C). The
median pair-wise distance was generally less sensitive
than the mean (Additional file 1: Figure S1), and the
results were robust over a broad range of genes used to
compute the distances (Additional file 1: Figure S2).
Based on these simulations, we selected the mean
within-cohort dispersion distance as the best metric to
describe intra-cohort transcriptional diversity.
Transcriptional and genomic diversity within TCGA breast
cancer subtypes
We assessed the transcriptional heterogeneity within the
four breast cancer subtypes as assigned by the PAM50 clas-
sifier using gene expression data from The Cancer Genome
Atlas (TCGA) breast cancer project (N = 547; Table 1) [4].
Gene expression data were used as provided and probe sets
with low expression or low variation across the dataset
were filtered as described in the Methods. Mean dispersion
distance was computed in groups of 100 cases from each
subtype, repeatedly sampled with replacement over 500
bootstrap iterations. Overall, tumors of the luminal A
subtype were significantly less heterogeneous than
other subtypes (permutation test P < 10-5), while basal-
like tumors had the highest transcriptionally diversity
Figure 1 Assessment of different transcriptional diversity metrics in simulated datasets. A) Simulated gene expression profiles generated
using a hierarchical model to independently control within sample (σg) and between samples (σp) transcriptional variation and the number of
latent subgroups. Each profile consists of 50 genes (rows) and 40 samples (columns). Profiles for 1, 2, 4 and 40 latent subgroups are shown for
low (σp /σg = 0.5/1.5) and high (σp /σg = 0.5/0.5) relative between-to-within sample variation. B) Transcriptional diversity within the simulated
profiles assessed using the mean pairwise Pearson distance, the mean pairwise cosine distance, or the mean dispersion distance. The boxplots
represent the distributions of these metrics obtained from 500 independent simulations of each dataset (blue: low σp /σg, green high σp /σg).
C) Same metrics as in B assessed in a two latent subgroup dataset of 40 samples with increasing proportion of the smaller subgroup. Boxplots
represent distribution over 500 independent simulations.
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Table 1 Breast cancer TCGA datasets used in this study
Data TCGA file link N
Tumor Information https://tcga-data.nci.nih.gov/docs/publications/brca_2012/BRCA.datafreeze.20120227.txt 466
PAM50 Subtype https://tcga-data.nci.nih.gov/docs/publications/brca_2012/BRCA.547.PAM50.SigClust.Subtypes.txt 466
Gene Expression-Level 3 http://tcga-data.nci.nih.gov/docs/publications/brca_2012/BRCA.Gene_Expression.Level_3.tar 547




Gene Models (RefSeq) UCSC table browser with track “RefSeq Genes” of genome version Feb. 2009 GRCh37/hg19 (http://genome.ucsc.edu/
cgi-bin/hgTables)
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within-patient and between-patient variance (see Methods)
showed that luminal A tumors had the highest within-
patient gene expression variance but the lowest between-
patient variance (smaller σp/σg ratio), whereas the reverse
was true for basal-like tumors that show a relatively narrow
range of expression within each tumor but more diverse
expression across tumors (Figure 2B). Comparing the
luminal subtypes, luminal B tumors appear transcription-
ally significantly more diverse (permutation test P < 10-5),
exhibiting a higher estimated σp/σg ratio, similar that of
HER2-enriched tumors (Figure 2A, B).
To examine whether the higher transcriptional diversity
observed in basal-like tumors is associated with greater
genetic heterogeneity, we evaluated the diversity in somatic
mutation profiles and DNA copy number variation as
categorical data using the mean pairwise Hamming dis-
tance [22] to assess intra-cohort diversity of genomic pro-
files (see Methods). The mean pairwise Hamming distance
was able to track the population diversity in the different
simulation scenarios (Additional file 1: Figure S3). As
observed at the transcriptome level, basal-like cancers
exhibited the highest diversity in the distribution of copy
number aberrations and the second highest mutational
heterogeneity, whereas luminal A tumors were genomically
the least diverse (Figures 2C, 2D). Our results are consist-
ent with the assessment in the original TCGA publication
that reported the highest overall rate of genome alteration
in basal-like tumors and the lowest in luminal A tumors
[4]. Moreover, the almost indistinguishable patterns of
molecular diversity that we observed in the genomic
and transcriptomic profiles of breast tumors suggest
that a measure of the transcriptional diversity could
be a effective surrogate measure of the underlying
genomic heterogeneity.Validation of transcriptional diversity patterns within
breast cancer subtypes using microarray datasets
We evaluated the generalizability of the results obtained on
the TCGA data using publicly available gene expression
datasets (Table 2) to assess the transcriptional diversity ofbasal-like (n = 403), HER2-enriched (n = 171), luminal A
(n = 515) and luminal B (n = 210) breast cancers. We cal-
culated the mean dispersion distance of transcriptional
profiles within each subtype over 500 bootstrap iterations
in groups of 100 cases per subtype. The pattern of tran-
scriptional diversity was very similar to that observed in
the TCGA dataset (Figure 2E), with basal-like cancers being
the most diverse and luminal A cancers being the most
uniform (permutation test P < 10-5), except that HER2-
enriched cancers in this cohort appeared less diverse.Basal-like breast cancers that respond to chemotherapy
are transcriptionally homogeneous
Among the 403 basal-like cases in the Affymetrix dataset,
255 cases received preoperative combination chemotherapy
(paclitaxel, 5-fluoracil, cyclophosphamide and doxorubicin),
which allowed us to compare the transcriptional diversity
of exceptionally chemotherapy sensitive cancers that
achieved pathological complete response (pCR, n = 96) to
those who had partial or no response as evidenced by viable
amounts or residual cancer after preoperative chemother-
apy (RD, n = 159)(Table 2). We compared the transcrip-
tional diversity of cancers from the two response groups by
calculating the mean dispersion distance in sets of 100 cases
per group over 500 bootstrap iterations. Chemotherapy
resistant basal-like cancers showed significantly greater tran-
scriptional diversity compared to chemotherapy sensitive
cancers (permutation test P < 10-5; Figure 2 F). These resist-
ant cancers had narrower within tumor expression range
but a greater variation between cancers (Figure 2G), and
also a greater number of latent transcriptionally homoge-
neous subtypes (Figure 2H). Our results provide evidence
that pathological complete response is associated with
significantly lower pretreatment transcriptional diversity,
corroborating previous reports of a significantly lower gen-
etic divergence in tumors achieving pCR [15].Transcriptional diversity extends at the level of individual
pathways
The varying degree of transcriptional diversity within dif-
ferent breast cancer subtypes raises the question whether
Figure 2 Characterization of transcriptional and genomic heterogeneity of breast cancer subtypes. A) Transcriptional diversity of cancers
within each subtype from the TCGA gene expression data [4] captured by the mean dispersion distance metric. B) Distributions of within and
between patient standard deviations of gene expression levels for each subtype estimated from the TCGA gene expression data. C) Genomic
heterogeneity of DNA copy number within each subtype estimated by the mean pairwise Hamming distance in the DNA copy number profiles
of cancers from the TCGA dataset. D) Mutational heterogeneity of subtypes estimated by the mean pairwise Hamming distance between the
somatic mutation profiles of cancers from the TCGA dataset. E) Transcriptional diversity of cancers from the Affymetrix U133A datasets assessed
using the mean dispersion distance metric. F) Transcriptional diversity based on mean dispersion distance of basal-like tumors that achieved pathological
complete response (pCR; n = 96) or had partial or no response (RD; n = 159) to preoperative chemotherapy. G) Estimated distributions of within and
between patient standard deviations of gene expression within the pCR and RD basal-like phenotypes. H) Patient-patient pairwise correlation plots
clustered to show substructure within the pCR and RD basal-like tumors. The scale for the Pearson correlation coefficient ranges from 0 (white) to 1
(blue). While chemo-sensitive tumors (pCR) show less structure, resistant tumors (RD) show a greater number of subgroups with relatively uniform
gene expression. Boxplots represent the distribution of the corresponding metric obtained from 500 bootstrap resampling iterations of 100 cases from
each subtype or subgroup.
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from a few pathways or whether it is more of a global
transcriptional phenomenon. We defined 50 pathways
from the Kyoto Encyclopedia of Genes and Genomes
(KEGG) [23] that represent all biological processes
but have minimal overlap in gene membership. Thenumber of genes in these pathways ranged from 11
(folate biosynthesis) to 389 (olfactory transduction)
(see Methods).
We applied the same bootstrapping procedure to
calculate the mean dispersion distance within breast
cancer subtypes, but now using only genes from each of
Table 2 Breast cancer Affymetrix U133A microarray datasets
GEO dataset N PAM50 subtype Response group basal-like
Basal Her2 LumA LumB Normal pCR RD
GSE11121 200 23 18 110 24 25 0 0
GSE20194 91 18 30 16 13 14 7 6
GSE20271 81 19 15 22 9 16 4 15
GSE2034 286 63 35 99 51 38 0 0
GSE22093 96 44 14 16 12 10 18 24
GSE25055 310 120 22 97 46 25 45 73
GSE25065 198 68 15 62 34 19 22 41
GSE7390 198 48 22 93 21 14 0 0
Total 1460 403 171 515 210 161 96 159
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of diversity across the four subtypes as that observed glo-
bally, suggesting that transcriptional diversity is a global
characteristic of the tumors and not primarily driven by
heterogeneity in a few biological processes (Figure 3A, C).
Certain pathways showed remarkably low diversity in all
subtypes indicating a tight transcriptional coordination of
genes involved in biological processes that are vital for all
cells (e.g. ribosome metabolism, protein export, glyoxy-
late/dicarboxylate metabolism; Figure 3A, B). Only a few
pathways were distinctively diverse within each subtype
(Figure 3C), and these were the same in all breast can-
cer subtypes (linoleic acid metabolism, renin/angioten-
sin system, and neuroactive ligand/receptor interaction)
(Figure 3A, B).
We also compared the pathway-level transcriptional di-
versity of chemotherapy sensitive (pCR) or resistant (RD)
basal-like cancers. Almost all pathways (48/50) were tran-
scriptionally more diverse in the chemotherapy resistant
group (Figure 3D), suggesting that the greater transcrip-
tional diversity in these tumors is global and not restricted
to certain pathways (slope of regression line = 0.917, 95%
confidence interval 0.877 to 0.956). Pathways with greater
diversity in RD cancers relative to pCR cancers included
basal-cell-carcinoma, which includes genes from the
Hedgehog, Wnt, TGF and p53 signaling pathways, folate
biosynthesis, and dorso-ventral axis formation pathway
involving genes from several key signaling pathways
including the MAPK and NOTCH (Figure 3D).
Discussion
In this study, we showed that the mean dispersion and
the mean pairwise Hamming distance provide quantita-
tive metrics that capture the transcriptional and genomic
diversity of breast cancer subtypes. We demonstrated
that each subtype is characterized by a different degree
of transcriptional and genomic diversity and provided
statistical evidence that basal-like breast cancers are the
most and luminal A cancers are the least heterogeneous.While this has been suggested in the literature [4,16,24] it
has never been previously demonstrated in statistical
terms. The difference in transcriptional diversity between
subtypes appears to concern the entire transcriptome with
the exception of a few biological processes that are critical
for cell survival, suggesting that basal-like and luminal A
cancers differ in fundamental ways in how tightly gene co-
expression is regulated within cells. These results are also
consistent with greater intratumor cellular heterogeneity
in basal-like cancers due to coexistence of either genomi-
cally different clonal populations or genomically similar
cells exhibiting greater diversity in cellular states. But
since we also observed identical trends in the relative
heterogeneity of DNA copy number alterations and som-
atic mutations between the subtypes, the results strongly
suggest that genomic alterations leave a major imprint on
transcriptional profiles [25] and likely drive the higher
transcriptomic diversity of basal-like cancers. Transcrip-
tional diversity can thus be considered as a surrogate
measure of the underlying genomic heterogeneity of can-
cers. To further elaborate, we would expect repeat biopsies
from a tumor with high intratumor heterogeneity to show
greater transcriptional diversity, as biopsies may consist of
different mixtures of clonal cells. High intratumor clonal
variation would also imply higher variation between two
such tumors and therefore a greater transcriptional
diversity.
We also demonstrated that two clinically very distinct
subtypes of basal-like cancers, chemotherapy resistant and
highly chemotherapy sensitive cancers, which cannot not
be reliably separated using gene expression based multi-
variate prediction models [17,18], show significant dif-
ferences in transcriptional diversity (permutation test
P < 10-5). Chemotherapy resistant cancers had much
greater transcriptional diversity across most biological
processes. Greater diversity in regulatory and meta-
bolic pathways could confer greater resilience against
cytotoxic insults [26]. Pathways that are expressed
more diversely in chemotherapy resistant basal-like
Figure 3 Transcriptional diversity of 50 KEGG biological pathways within breast cancer subtypes from the Affymetrix dataset.
A) Heatmap of mean dispersion distance within breast cancer subtypes considering genes in each of the 50 KEGG pathways. Pathways (rows) are
ranked from the least diverse at the top to the most diverse at the bottom. Blue represents low and red high mean dispersion. B) Detailed expression
heat maps for basal-like cancers showing the heterogeneity of gene expression for genes in the least heterogeneous (ribosome metabolism; top) and
the most heterogeneous pathways (linoleic acid metabolism; bottom). Blue represents low and red high expression level. C) Distribution of
pathway-based transcriptional diversity within each subtype. Pathway-level mean dispersion distances were calculated by bootstrap as
described in Supplementary Methods. D) Comparison of pathway-level transcriptional diversity between two clinically distinct phenotypes of
basal-like cancers, an extremely chemosensitive (pCR) and a chemoresistant (RD). Points on the plot represent the average pathway-level mean pairwise
dispersion obtained from boostrap within each of the 50 pathways. The dashed red line is the diagonal, indicating equal transcriptional diversity between
the two response phenotypes. The regression line (blue solid line) its 95% pointwise confidence interval (grey area) is consistently below the diagonal
suggesting greater transcriptional diversity for RD cancers throughout the 50 pathways. Pathways that were extreme outliers from the trend described by
the regression line were identified by quantile-quantile plots of the standardized residuals. These pathways are indicated with letters as following:
A – sphingolipid meta, B – SNARE interactions in vesicular transport, C – basal cell carcinoma, D – dorso-ventral axis formation, E – non-homologous end
joining (DNA repair), F – folate biosynthesis.
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anisms of chemotherapy resistance.
Finally, our results generate new insights as to why it may
be difficult to predict chemotherapy response in basal-like
cancers. Due to the greater transcriptional diversity in
chemotherapy resistant tumors, a single gene expressionsignature of resistance would fail to represent adequately
the spectrum of resistance mechanisms present and thus
limit the sensitivity and accuracy of such predictors. This
has been demonstrated to be the case recently through
insightful simulations [27]. Using genomic DNA copy
number alterations to substratify basal-like cancers into
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predictability, but this strategy will require considerably lar-
ger cohorts. Alternatively, using a single metric that cap-
tures the within-patient molecular heterogeneity may prove
a more effective strategy to predict general chemotherapy
sensitivity of a given cancer.
Conclusion
We presented and systematically evaluated a quantitative
measure to capture transcriptional and genomic diversity
among cancers. Results from different types of genomic
data consistently demonstrated that basal-like cancers are
the most heterogeneous while luminal A the least. Such
diversity appears to be a global characteristic reflected in
most biological process. Finally, we also showed that
greater transcriptional diversity is also associated with
basal-like cancers that are resistant to chemotherapy,
suggesting that molecular heterogeneity is a manifestation,
potentially a causal one, of treatment resistance. This also
explains the difficulty in developing generalizable gene
signatures that are predictive of chemotherapy response in
the highly heterogeneous triple-negative breast cancers.
Methods
Breast cancer datasets and processing
The Cancer Genome Atlas (TCGA) Dataset
Datasets were downloaded from the TCGA breast carcin-
oma web site (https://tcga-data.nci.nih.gov/docs/publica-
tions/brca_2012/) [4] (Table 1). Gene expression data by
Agilent 244 K arrays were available for 547 cases. DNA
copy number alteration data by Affymetrix 6.0 SNP arrays
were available for 466 cases. Somatic mutation data by
whole exome sequencing were available on 463 cases. The
TCGA PAM50 subtype classification was downloaded also
from the same site. A sample list is provided in Additional
file 2: (TCGA sample ID.xlsx).
Affymetrix U133A dataset
A total of 1460 breast cancer profiles from eight breast
cancer datasets that were uniformly profiled on the
Affymetrix U133A microarray were obtained form the
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/). Because of partial overlap in several of these datasets,
the selected unique samples from each GEO dataset are
provided in Additional file 3: (Affy_sample_info1460.txt). A
summary of the combined data set is given in Table 2.
Data preprocessing
The TCGA gene expression data were used as provided
without any additional processing. The segmented log2
DNA copy number values were trichotomized as deletion
(score < -0.3), amplification (score > 0.3) or no effect. We
aggregated the segment-level alterations at the gene level
using RefSeq gene models. A gene was labeled as deletedor amplified if the entire transcribed region was in a
deleted or amplified segment. Of the 45,918 RefSeq genes,
22,271 were amplified or deleted in at least one of the
patients in the cohort and were used in the calculation of
the Hamming distance. The somatic mutation data were
provided at the gene level in the TCGA dataset (any muta-
tion vs no mutations) and did not require any further
processing.
The Affymetrix U133A data files were compiled in a sin-
gle dataset, normalized by MAS5, scaled to a target inten-
sity of 600 and log2 transformed. Principal component
analysis (PCA) was applied to detect potential batch effects
across the datasets. We used the empirical Bayes frame-
work procedure ComBat [28] as implemented in the R
package sva [29] to remove batch effects due to different
datasets. We used PCA after batch effect removal to verify
lack of batch effects after correction (Additional file 1:
Figure S4). A previously validated PAM50 algorithm for
Affymetrix-based expression data was used to generate
breast cancer subtype classification for each cancer in the
dataset [30]. Table 2 provides a summary of all the data-
sets used in this study and the subtype distribution within
each dataset. The 161 normal-like cases were excluded
from the analysis. Prior to analysis, the combined, batch-
adjusted dataset was filtered to remove probe sets in the
lowest expression quartile and those in the lowest median
absolute deviation (MAD) decile. The remaining 14,505
probe sets were used in subsequent analyses.
Collection and processing of KEGG pathways
The 186 pathways used in this study were collected from
the Molecular Signatures Database [31] (MSigDB; http://
www.broadinstitute.org/gsea/msigdb/index.jsp) and cor-
respond to gene sets derived from the KEGG pathway
database [23] (http://www.genome.jp/kegg/pathway.html).
We processed the original list of 186 pathways to produce
a reduced set of pathways that had minimal overlap in
gene membership. We broadly followed the steps
described previously [32]. First, we calculated a matrix
of pairwise pathway similarities derived from the hyper-
geometric distribution as follows. If N, NA and NB
represent the genes in all pathways, in pathway A and
in pathway B respectively, and these two pathways have
n genes in common, then the degree of enrichment of
pathway B in genes also included in pathway A is given
by the hypergeometric distribution h(N, NA, NB) [33].
This can be visualized as a 2x2 contingency table
cross-tabulating the number of genes in the two path-
ways (pathway A vs not pathway A by pathway B vs
not pathway B). The objective is to test whether genes
in pathway B are over-represented among genes in
pathway A compared to genes not in pathway A. Thus
a rejection of the null hypothesis of independence be-
tween the two dimensions of the 2x2 table is evidence for
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pathways. If we let X denote the number of genes in com-
mon, then the probability of two unrelated pathways (under
the null hypothesis) having at least n genes in common is
given by












Pathways for which the null hypothesis was rejected at
the 0.05 level, i.e P(X ≥ n) < 0.05 were labeled as similar
(value of 1) and the remaining as dissimilar (value of 0) in
the pathway similarity matrix. Pathways with the highest
degree of overlap were identified as those with the highest
row or column sum in the similarity matrix and were
removed recursively by removing both the corresponding
column and the row from the pathway similarity matrix.
The resulting 50 pathways consisted of almost disjoint
genes sets and were used in subsequent analyses.
Distance measures
Pearson distance
If the pairwise Pearson’s correlation coefficient between
two expression vectors (profiles) is denoted by ρ, the
Pearson’s pairwise distance was calculated as
DPearson ¼ 1−ρ2
All the unique pairwise distances within a set of profiles
are computed and the distribution of pairwise distances is
summarized by its mean or its median.
Cosine distance











where ‖X‖ represents the L2-norm of vector X. The com-
mon definition of the cosine similarity measure is the co-
sine of the angle between two vectors. Here, we define the
cosine dissimilarity or distance measure as the normalized
angle between the two vectors. The above two dissimilarity
measures are related, since the Pearson’s correlation is es-
sentially equivalent to a centered cosine similarity measure:
DPearson x; yð Þ ¼ 12 1−cos
π
2
Dcosine x−x; y−yð Þ
n oh i
As above, all the unique pairwise distances within a
set of profiles are computed and the distribution of pair-
wise distances is summarized by its mean or its median.Dispersion distance
For the calculation of dispersion distances, the distance
matrix A of all pairwise Pearson distances is centered by
subtracting the row and column means and then adding
the overall mean to each element of A. The spectral de-
composition of the resulting centered matrix defines the
principal coordinates. Vectors are mapped to the full prin-
cipal coordinate space and their Euclidian distance from
the overall centroid in this space defines the distance or
dissimilarity from each vector to its centroid [34]. The
overall dispersion distance for a set of vectors is then cal-
culated as the mean or median dispersion over all vectors.
Computations were performed using the R language pack-
age vegan [35].
Hamming distance
For categorical vectors we used the pairwise Hamming
distance for character strings (not ordinal) to assess
dissimilarity [22]. Specifically, for categorical vectors Xi ,




δ Xik ; Xjk
 
where δ(a, b) = 1 when a is the same as b and zero
otherwise. The overall Hamming dispersion distance for
the set of categorical profiles was computed as the mean
or median pairwise Hamming distance.
Permutation test for assessing significance in difference of
mean distances
We used a permutation procedure to compare the boot-
strap estimates of the mean group distances between two
groups of samples. Two vectors, each containing 500 boot-
strap estimates of the mean distance within each group,
were concatenated to form a 1000 element vector. This
vector was resampled without replacement 105 times and
for each permutation the average of the first 500 elements
was compared to the average of the last 500 elements. This
difference was then compared to the original difference in
the mean distances between the two groups. The p-value,
which represents the probability of observing by chance a
difference between the bootstrapped mean distances at
least as high as the observed, was then computed as (1 + #
(D > d))/(1 + R), where D is the difference in means from
the permuted vectors, d is the difference in means from the
original vector, and R = 105 is the number of random
permutations.
Generation of simulated datasets
We used the Umpire R language package to simulate realis-
tic gene expression datasets with controlled within and be-
tween patient variation in gene expression [20]. In each
simulated scenario we considered 50 genes per case and 40
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patients and that the expression of each gene across
patients follows a log-normal distribution with parameters
μg and σP, i.e. log(Xi) ∼Normal(μg, σP). The mean log
expression μg is assumed to have a normal distribution
across genes with mean μ0 and standard deviation σg, i.e.
μg ∼Normal(μ0, σg). It was further assumed that the
between-sample gene expression variance σP follows an in-
verse Gamma distribution with hyperparameters α = 15 and
β = 7, which correspond to a mean σP equal to 0.5. The
mean μ0 was set equal to 8 for all simulations. In the first
scenario shown in Figure 1A, the within sample standard
deviation σg was set to 1.5, whereas in the second scenario
it was set to 0.5. Samples from different latent groups were
generated by resampling with the same set of hyperpara-
meters. Additional file 1: Figure S5 shows the effect of the
various parameters of the hierarchical model on the esti-
mated diversity of the resulting set of gene expression
profiles. Binarized profiles were simulated in the same
way and then thresholded using the function Z > 1.5,
where Z = (X – M)/SD, X is the continuous gene expres-
sion value and M, SD are the gene-wide and sample-wide
(overall) mean and standard deviation of expression.Estimation of gene expression statistics from profiles
If Xij is the expression of gene i in sample j then mi = E
(Xij) is the centroid of gene expression levels, which is also
expressed more compactly as m = EP(X). The mean of
the centroid vector is the overall mean expression or
μ0 = Eg(m) = Eg(EP(X)). The within sample variance is
estimated from the variance of the centroid vector as
σ2g ¼ Vg mð Þ ¼ Vg EP Xð Þð Þ . Finally, the between sample
variance is estimated from the mean of the variance
vector s2 = VP(X), or σ2P ¼ Eg s2ð Þ ¼ Eg VP Xð Þð Þ.
Additional file 1: Figure S6 shows the parameters esti-
mated from the simulated scenarios shown in Figure 1A.
The between sample standard deviation (SD) was set to 0.5
in all these scenarios. As shown in Additional file 1: Figure
S6A, the between sample SD estimate is nearly unbiased
when there is one latent group, with the variance of the es-
timate being very small in the low between-to-within SD
scenario (S) but considerably larger in the high between-to-
within SD scenario (U). Furthermore, an increasing number
of latent groups results in greater between sample SD,
reflecting the greater population diversity, but the effect is
more moderate in the high between-to-within SD scenario
(U). Similarly, the estimate of the mean within sample SD
is nearly unbiased (1.5 for S and 0.5 for U) when there is
one latent group, but an increasing number of latent groups
reduces the estimate of the within sample SD. Therefore, a
greater number of latent groups in a cohort will be bias up-
wards the estimated between sample variance and bias
downwards the estimated within sample variance.Scripts/Code
All the R scripts required to generate the datasets and
run the analyses presented in this manuscript are pro-
vided in Additional file 4.
Additional files
Additional file 1: Supplementary Figures.
Additional file 2: TCGA_sample ID.txt: tab-delimited text file listing
the sample, PAM50-subtype classification, and whether gene
expression, somatic mutation or copy number variation data was
available for each sample.
Additional file 3: Affy_sample_info1460.txt: tab-delimited text file
listing the GEO sample id, GEO dataset series id, the response
category (pCR/RD) or NA if not available, and the PAM50-subtype
classification.
Additional file 4: Jiang_RScripts.zip: Archive containing R scripts
for the analyses presented in this manuscript. Scripts included:
supply-code-simulation. R Code for generating simulated expression
datasets and heterogeneity calculation. supply-code-TCGA.R Code for
TCGA data import, heterogeneity calculation and comparisons. supply-code-
het-affy.R Code for Affymetrix data normalization, heterogeneity calculation
and comparisons. KEGG_Path_NonOverlap.R Code for generation of 50
KEGG pathways with minimum degree of overlap in gene membership. File
“186KEGG.Rdata” with KEGG pathway gene lists needed by this script is also
provided.
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